ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

HHS Inquiry Triggers Sloppy Stories On Gallo’s Laboratory

July 21, 1989

ASCO, NCCS form cancer quality alliance.

November 11, 2005

NCCN and Pfizer Issue RFP In Renal Cell Carcinoma Or Hematologic Malignancies

October 25, 2013

NCI Health Disparities Center Describes “Think Tank” Projects For Policy Change.

April 27, 2001

ACS Encourages Grant Applications In All Aspects Of Pain Control

May 7, 1993

Study Links Exercise and Survival In Breast and Colon Cancer Mortality

May 25, 2012